Business

Unfractionated Heparin Market 2018 Industry Analysis, Top Company, Research Forecast, Analysis and Supply Demand Report 2026 : United States

Unfractionated Heparin Market
Unfractionated Heparin Market

Unfractionated heparin (UFH)is a natural agent widely used to prevent clot formation in vessels. Unfractionated heparin is a fast-acting blood thinner, which works with antithrombin, a natural protein in the body, to block clot formation. UFH is administered to patient intravenously into an arm vein or as a subcutaneous injection under the skin. UFH can also be administrated orally. However, oral absorption of unfractionated heparin is poor, owing to their size and anionic structure. UFH is not absorbed properly from the gastrointestinal tract when taken orally.

Unfractionated Heparin Market – Regional Analysis

On the basis of region, the unfractionated heparin market is segmented into North America, Latin America, Europe, Middle East, Asia Pacific, and Africa. North America holds a leading position in the global unfractionated heparin market, owing to increasing prevalence of deep venous thromboembolism and Pulmonary Embolism in the region. For instance, according to the Centers for Disease Control and Prevention (CDC), February 2018 data findings, around 60,000 to 100,000 people are estimated to die due to DVT/PE, in the U.S. Moreover, 10% to 30% of people die within one month from diagnosis. Additionally, according to the same source, around 5% to 8% of the U.S. population has one of several genetic risk factors, such as inherited thrombophilias, which increases the risk for thrombosis.

Download PDF Brochure Of This Research Report @ https://www.coherentmarketinsights.com/insight/request-pdf/1672

Unfractionated Heparin Market Competitive Landscape

Some of the key players operating in the unfractionated heparin market are B. Braun Melsungen AG, Pfizer, Inc., Baxter International Inc., Siemens Ag, Sagent Pharmaceuticals, Inc., and LEO Pharma A/S.

Research advancements in unfractionated heparin are expected to create new applications in the treatment of Chronic Obstructive Pulmonary Disease (COPD). A pilot study performed at the University of Portsmouth in December 2017, evaluated that, the use of inhaled nebulized unfractionated heparin is an effective treatment for moderate-to-severe COPD. Unfractionated heparin significantly improves the lung function and reduces labored breathing.